The RUCONEST® (C1 esterase inhibitor [recombinant]) Account Takeovers have been selected as this year’s Innovative Strategy in the PM360 Innovations Issue.
In 2021, Pharming partnered with Snow Companies to transform RUCONEST’s social media channels. We launched four patient “account takeovers” of Pharming’s Facebook and Instagram accounts. During the campaign, four hereditary angioedema (HAE) patients each published separate weekday posts about their patient journeys. Read more here: https://www.pm360online.com/pm360-2021-innovative-strategy-ruconest-c1-esterase-inhibitor-recombinant-account-takeovers-from-snow-companies-and-pharming/https://www.pm360online.com/pm360-2021-innovative-strategy-ruconest-c1-esterase-inhibitor-recombinant-account-takeovers-from-snow-companies-and-pharming/